摘要
目的评价门冬氨酸-鸟氨酸治疗黄疸型慢性病毒性肝炎的临床疗效。方法将108例黄疸型慢性病毒性肝炎患者随机分为3组,分别接受4周的门冬氨酸-鸟氨酸、腺苷蛋氨酸和门冬氨酸钾镁等治疗,并检测患者治疗前后的血清总胆红素。结果门冬氨酸-鸟氨酸和腺苷蛋氨酸组在4周治疗结束时降低血清总胆红素的有效率分别为75.0%和72.2%,显著高于门冬氨酸钾镁组(30.6%),P<0.01;门冬氨酸-鸟氨酸与腺苷蛋氨酸组患者血清总胆红素每日降幅分别为4.3μmol/L±5.1μmol/L和4.3μmol/L±5.6μmol/L,显著高于门冬氨酸钾镁对照组(2.1μmol/L±8.3μmol/L),P<0.01。结论注射用门冬氨酸-鸟氨酸粉针剂能有效降低黄疸型慢性病毒性肝炎患者的血清总胆红素水平。
Objective Aim To evaluate clinical efficacy of L-ornithine-L- aspartate in the management of icteric chronic viral hepatitis. Methods 108 patients with icteric chronic viral hepatitis were randomly divided into three groups,who received 4 weeks treatment with intravenous L-ornithine-L-aspartate,S-adenosyl-L-methionine, potassium magnesium aspartate, respectively. The serum total bilirubin was tested in all patients at the onset and the end of treatment. Results The effective rates of lowering serum total bilirubin were 75.0% and 72.5% respectively in the group with L-ornithine-L-aspartate and S-adenosyl-L-methionine, which were significantly higher than that in the group with potassium magnesium aspartate （30.6%）, P 〈 0.01. The daily levels of decreased serum total bilirubin were 4.3 ± 5.1μmol/L and 4.3 ± 5.6μmol/L respectively in the group with L-ornithine-L-aspartate and S-adenosyl-L-methionine, which were significantly higher than that in the group with potassium magnesium aspartate （2.1 ± 8.3 μmol/L） ,P 〈 0.01. Conclusion The levels of serum total bilirubin are effectively decreased in the patients with icteric chronic viral hepatitis by the management of intravenous L-ornithine-L-aspartate.
出处
《临床内科杂志》
CAS
2007年第4期256-258,共3页
Journal of Clinical Internal Medicine
